Sera Prognostics (SERA) Preferred Stock Liabilities (2020 - 2021)
Sera Prognostics' (SERA) quarterly Preferred Stock Liabilities came in at $149.1 million in Q2 2021, up 91.59% YoY from $77.8 million in Q2 2020, and up 34.97% on a QoQ basis from $110.5 million in Q1 2021.
Sera Prognostics (SERA) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Sera Prognostics (SERA) has 2 years of Preferred Stock Liabilities data on file, last reported at $149.1 million in Q2 2021.
- Quarterly Preferred Stock Liabilities rose 91.59% year-over-year to $149.1 million in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $149.1 million (up 91.59% YoY) and the FY2020 annual result came in at $474000.0, changed N/A from the prior year.
- Preferred Stock Liabilities improved to $149.1 million in Q2 2021, from $110.5 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $149.1 million in Q2 2021 to a low of $474000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | - |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | - |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | - |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | - |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | - |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | - |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | - |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | - |
| 10 | Sera Prognostics | 103.48 Mn | 103.48 Mn | -20,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 149.14 Mn |
| Mar 31, 2021 | 110.50 Mn |
| Dec 31, 2020 | 474,000.00 |
| Sep 30, 2020 | 77.84 Mn |
| Jun 30, 2020 | 77.84 Mn |